CAMBRIDGE, Mass., Aug. 14, 2026
Enveric Biosciences reported continued progress in the preclinical development of EB-003, its lead next-generation neuroplastogenic small molecule being developed as a potential treatment for neuropsychiatric disorders. During the second quarter of 2026, the company advanced multiple IND-enabling studies supporting a planned Investigational New Drug application and future initiation of a Phase 1 clinical trial. New preclinical findings further supported EB-003’s differentiated pharmacological profile, including results from a highly sensitive GloSensor™ cAMP assay showing that the compound consistently exhibited a non-hallucinogenic profile. These findings complement previously reported BRET assay results and strengthen the scientific rationale for advancing EB-003 toward first-in-human evaluation.
EB-003 Shows Non-Hallucinogenic Preclinical Profile
EB-003 remains the central focus of Enveric Biosciences’ development strategy, with the company working to establish a preclinical safety and pharmacology package suitable for an IND submission. During the quarter, the GloSensor™ assay provided additional evidence supporting the compound’s non-hallucinogenic characteristics, complementing earlier BRET assay findings. Enveric is developing EB-003 as a next-generation neuroplastogenic therapy designed to potentially retain therapeutic effects associated with neuroplasticity while avoiding the hallucinogenic effects associated with some psychedelic-inspired compounds. The company also reported favorable results from in vitro photoreactivity studies, which showed that EB-003 did not exhibit photoreactive potential. This finding is relevant to the compound’s continued development as a potential therapy intended for repeated or chronic use in patients with psychiatric and neurological disorders. Together, the pharmacological and photoreactivity findings provide additional support for continued advancement of the program
IND-Enabling Studies Move Forward
Enveric has continued building the IND-enabling safety package required before clinical testing of EB-003 can begin. During the second quarter, the company initiated genotoxicity studies to evaluate whether EB-003 could interact with DNA or potentially cause genetic mutations. Genotoxicity assessment is an important component of the preclinical safety evaluation required to support an IND submission. The company expects to complete the remaining IND-enabling activities and subsequently submit its planned application to support a Phase 1 first-in-human study. EB-003 is designed to selectively engage 5-HT2A and 5-HT1B receptors, with Enveric investigating its potential to produce rapid and durable antidepressant and anxiolytic effects without hallucinogenic activity. The company’s current development strategy therefore centers on progressing the compound from laboratory-stage characterization toward clinical evaluation while continuing to address key safety and regulatory requirements.
Advertisement
Enveric Expands Neuroplastogenic Platform and IP
Alongside EB-003 development, Enveric Biosciences expanded its intellectual property position around its broader neuroplastogenic platform. The company secured U.S. Patent No. 12,605,361, covering methods of treating psychiatric disorders using compounds from its EVM301 Series of proprietary tryptamine-derived neuroplastogens. Enveric also received a Notice of Allowance from the USPTO for a patent application covering its EVM401 Series of proprietary methylone-inspired neuroplastogens. These developments strengthen protection around additional compounds being investigated for potential applications in mental health disorders. Financially, Enveric reported a $3.0 million net loss for the second quarter of 2026 and held approximately $8.3 million in cash as of June 30, 2026. The company also raised approximately $5.0 million in gross proceeds through a private placement and approximately $1.5 million through warrant exercises. As Enveric enters the second half of 2026, its primary development priorities remain completion of EB-003 IND-enabling studies, submission of the planned IND application, and advancement toward a Phase 1 clinical trial.
Source: Enveric Biosciences press relese
